Thyroid cancer is frequently associated with the oncogenic conversion of receptor tyrosine kinases (RTKs) or their downstream signalling molecules. Hence, there is a strong biological rationale for assessing the efficacy of RTK blockade to treat patients who are resistant to or not candidates for treatment with radioactive iodine. The first results of clinical trials based on the use of RTK inhibitors in thyroid cancer patients have recently been published. Here we discuss targeting of specific RTKs as a potential therapeutic strategy for the treatment of thyroid cancer.
|Number of pages||16|
|Journal||Best Practice and Research: Clinical Endocrinology and Metabolism|
|Publication status||Published - Dec 2008|
- monoclonal antibody
- small-molecule inhibitor
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism